Incyte – US Biotech Company Impresses with Promising Pipeline!
Reading Time: 2 minutes
Business Drivers: The US biotech company Incyte (INCY) specializes primarily in the development of new drugs and therapies for the treatment of rare diseases. With Jakafi, a medication for rare blood disorders such as myelofibrosis and polycythemia, they have a blockbuster with an annual revenue of 2 billion USD. By acquiring the biotech company Escient Pharmaceuticals, they secure access to two promising drug candidates in early clinical testing for the treatment of rare skin diseases such as Atopic Dermatitis (EP262) and Cholestatic...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
